Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data

• Published in: BMC pulmonary medicine 2022-10, Vol.22 (1), p.1-383, Article 383
• Main Authors: Weiss, Tracey J, Rosen Ramey, Dena, Yang, Lingfeng, Liu, Xinyue, Patel, Mahesh J, Rajpathak, Swapnil, Bajwa, Ednan K, Lautsch, Dominik
• Format: Article
• Language: English
• Subjects: Algorithms; Analysis; Cardiovascular disease; Care and treatment; Chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease; Complications and side effects; Diagnosis; Drug dosages; Drug therapy; Endothelins; Hypertension; Lung diseases; Lung diseases, Obstructive; Obstructive lung disease; Patients; Phosphodiesterase; Practice guidelines (Medicine); Pulmonary function tests; Pulmonary hypertension; Pulmonary hypertension; Pulmonology; Respiratory function; Retrospective study; Risk factors; Sensitivity analysis
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-022-02167-9

Background Pulmonary hypertension (PH) is a serious complication of chronic obstructive pulmonary disease (COPD). While clinical guidelines recommend specific drug therapies for pulmonary arterial hypertension (PAH), these drug therapies are not recommended for PH due to lung disease. Methods This was a retrospective cohort study using the Optum[R] Clinformatics[R] Data Mart from January 2009-September 2019. An algorithm was designed to identify adults with [greater than or equal to] 2 ICD-9-CM or ICD-10-CM diagnosis codes for PH and with [greater than or equal to] 2 diagnosis codes for COPD. Sensitivity analyses were conducted among subgroups of patients with evidence of a right heart catheterization (RHC) or pulmonary function test (PFT). Patient characteristics, medications used, and durations of use of PAH and COPD medications were analyzed. Results A total of 25,975 patients met the study inclusion criteria. Their mean age was 73.5 (SD 10.0) years and 63.8% were female. Medications targeting PAH were prescribed to 643 (2.5%) patients, most frequently a phosphodiesterase-5 inhibitor (2.1%) or an endothelin receptor antagonist (0.75%). Medications for COPD were prescribed to 17,765 (68.4%) patients, most frequently an inhaled corticosteroid (57.4%) or short-acting beta agonist (50.4%). The median durations of use ranged from 4.9 to 12.8 months for PAH medications, and from 0.4 to 5.9 months for COPD medications. Of the subgroup of patients with RHC (N = 2325), 257 (11.1%) were prescribed a PAH medication and 1670 (71.8%) used a COPD medication. Of the subgroup with a PFT (N = 2995), 58 (1.9%) were prescribed a PAH medication and 2100 (70.1%) a COPD medication. Conclusions Patients with PH associated with COPD were identified in a US administrative claims database. Very few of these patients received any of the medications recommended for PAH, and only about two thirds received medications for COPD. Keywords: Hypertension, Pulmonary hypertension, Retrospective study, Chronic obstructive pulmonary disease, Drug therapy, Algorithms